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Methods The number of lymphocytes and NK cells, and 
NK cell activity, were assessed using flow cytometry and a 
51Cr release assay, respectively.
Results A total of 26 patients with untreated ATL or 
PTCL were enrolled, and blood samples from 25 patients 
were evaluable. NK cell number in ATL decreased after 
mLSG15/-L treatment, and the degree of decrease in the 
NK cell number was more prominent just before VECP 
therapy (Day 15–17 of each cycle) than just before VCAP 
therapy (Day 1 of each cycle). The NK cell number in ATL 
after CHOP/-L treatment also decreased. Interestingly, the 
NK cell activity showed a tendency to increase after the 
treatment. NK cell number in PTCL did not decrease by 
CHOP/-L regimen, but the activity was slightly decreased 
after the treatment.
Conclusions These results indicate that the effects of 
chemotherapeutic agents on NK cells vary according to the 
disease type and intensity of chemotherapy.
Keywords Antibody · ATL · Chemotherapy · NK cell · 
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Abbreviations
ADCC  Antibody-dependent cellular cytotoxicity
AITL  Angioimmunoblastic T-cell lymphoma
ALCL  Anaplastic large cell lymphoma
ALK  Anaplastic lymphoma kinase
ATL  Adult T-cell leukemia–lymphoma
CCR4  Chemokine receptor 4
CD  Cluster of differentiation
CHOP  Cyclophosphamide, doxorubicin, vincris-
tine, and prednisone
JCOG  Japan Clinical Oncology Group
mLSG15  VCAP–AMP–VECP; vincristine, cyclo-
phosphamide, doxorubicin, and prednisone; 
Abstract 
Purpose Natural killer (NK) cells are well known to be the 
most important effector cells mediating antibody-dependent 
cellular cytotoxicity (ADCC) which is an important mecha-
nism of action of antibody drugs. We evaluated the effects of 
chemotherapy on the cell number and activity of NK cells 
from patients who received the vincristine–cyclophospha-
mide–doxorubicin–prednisone (VCAP), doxorubicin–rani-
mustine–prednisone (AMP), and vindesine–etoposide–car-
boplatin–prednisone (VECP) (mLSG15) or mLSG15-like 
(-L) regimen, which is one of the standard of cares for newly 
diagnosed adult T-cell leukemia–lymphoma (ATL), or the 
cyclophosphamide–doxorubicin–vincristine–prednisone 
(CHOP) or CHOP-L regimen which is another standard of 
care for ATL and peripheral T-cell lymphoma (PTCL).
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doxorubicin, ranimustine, and prednisone; 
and vindesine, etoposide, carboplatin, and 
prednisone
NK  Natural killer
OS  Overall survival
PTCL  Peripheral T-cell lymphoma
PTCL-NOS  Peripheral T-cell lymphoma, not otherwise 
specified
SSC-H  Side scatter-height
Introduction
ATL belongs to the category of mature T/NK-cell neo-
plasms [1] and occurs secondary to HTLV-1 infection [2–
4]. ATL frequently occurs in the HTLV-1 endemic area in 
Kyushu islands, the western part of Japan [5], and its prog-
nosis is the worst among common subtypes of mature T/
NK-cell neoplasms [6]. Recently, VCAP–AMP–VECP reg-
imen (mLSG15), which was a modified version of LSG15 
[7], developed by the Japan Clinical Oncology Group 
(JCOG) has been established as a standard of care in newly 
diagnosed aggressive ATL [8]. However, the results are still 
not satisfactory, with a median survival of 13 months and 
a 3-year overall survival (OS) rate of only 24 % [9]. Other 
mature T/NK-cell neoplasms include peripheral T-cell 
lymphoma, not otherwise specified (PTCL-NOS), angio-
immunoblastic T-cell lymphoma (AITL), and anaplastic 
large cell lymphoma (ALCL). These disease subtypes are 
collectively called PTCL [1]. The current standard of care 
for PTCL is CHOP therapy including the CHOP-L regimen 
[10]; however, it has been reported that PTCL shows a gen-
erally poor prognosis, with 5-year OS rates of only 32 % in 
PTCL-NOS and AITL, except for in anaplastic lymphoma 
kinase (ALK)-positive ALCL, which is associated with a 
5-year OS rate of 70 % [6].
In recent years, the efficacies of various therapeutic 
monoclonal antibody (mAb)-based monotherapies have 
been investigated in PTCL. These mAbs include the anti-
CD52 mAb alemtuzumab [11, 12], the anti-CC chemokine 
receptor 4 (CCR4) mAb mogamulizumab [13–15], and 
the anti-CD30 antibody drug conjugate mAb, brentuxi-
mab vedotin [16]. Based on evidence indicating that a 
combination of the anti-CD20 mAb rituximab [17], and 
chemotherapy including CHOP therapy achieved a marked 
improvement in therapeutic efficacy in patients with B-cell 
non-Hodgkin lymphomas, the combination of mAbs and 
chemotherapy is expected to represent a promising regimen 
for mature T/NK-cell neoplasms.
ADCC is an important tumor cell-killing mechanism of 
action of mAbs including the anti-CCR4 mAb mogamuli-
zumab, which has been approved for CCR4-positive ATL 
and relapsed/refractory PTCL in Japan. Mogamulizumab is 
a defucosylated mAb, resulting in highly enhanced ADCC 
by increased binding affinity to the Fcγ III receptor (CD16) 
on effector cells [18–20]. It has been also shown that the 
ADCC of mogamulizumab mainly depends on the amount 
of effector cells such as CD16/CD56 double-positive NK 
cells [19]; however, to our knowledge, there have been no 
reports regarding the effects of various chemotherapeu-
tic agents on CD16/CD56 double-positive NK cells cause 
high ADCC or other effector cells to date. In this regard, 
we carried out the present study to evaluate the effects of 
two first-line therapies, namely the mLSG15 or mLSG15-
L (mLSG15/-L) and CHOP or CHOP-L (CHOP/-L) regi-
mens, on NK cell number and activity in newly diagnosed 
ATL and PTCL patients.
Materials and methods
Study design
This study was carried out in four institutions (Nagoya 
Daini Red Cross Hospital, Nagoya City University Hospital, 
Nagasaki University Hospital, and Imamura Bun-in Hos-
pital) in collaboration with Kyowa Hakko Kirin Co., Ltd. 
(Tokyo, Japan) from May 2009 to November 2010. As per 
the study protocol, blood samples were collected at speci-
fied time points from patients with newly diagnosed ATL or 
PTCL receiving the mLSG15/-L regimen or CHOP/-L regi-
men as the primary treatment. Cell numbers of lymphocytes 
and NK cells, and NK cell activity, were determined by flow 
cytometry, and 51Cr release assay, respectively [21]. Blood 
samples were obtained at eight time points before the VCAP 
and VECP therapies in the first to the fourth cycle of the 
mLSG15/-L regimen, and at eight points before the first to 
the eighth cycle of the CHOP/-L regimen. A blood sample 
of 10 mL was obtained at each time point, and the measure-
ment was terminated when the treatment was discontinued 
or changed to another treatment.
Blood samples were also collected from healthy adult 
volunteers in a clinical research institution between 
November and December 2009, and their NK cell number 
and activity were measured in the same manner.
Patients and healthy adult volunteers
Patients with newly diagnosed and previously untreated 
ATL (acute, lymphoma, or unfavorable chronic type) or 
PTCL aged 20 years or older to whom it was planned to 
administer the mLSG15/-L or CHOP/-L regimen were eligi-
ble for the study. The unfavorable chronic type of ATL was 
defined by the presence of at least one of the following three 
factors: low serum albumin, high lactate dehydrogenase, or 
high blood urea nitrogen concentration [9].
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The healthy adult volunteers were aged 40 or above 
who were negative for hepatitis B virus surface antigen, 
hepatitis C virus antibody, human immunodeficiency virus 
antibody, or syphilis test such as rapid plasma regain and 
treponema pallidum hemagglutination test. The blood test 
for HTLV-1 antibodies was not carried out for healthy adult 
volunteers. They had also no past history of allergic dis-
eases such as atopic dermatitis, bronchial asthma, or hay 
fever. All patients and healthy adult volunteers signed writ-
ten informed consent.
Evaluation criteria and endpoint
The immune status was evaluated in all eligible patients, 
and variations in NK cell number and activity before, dur-
ing, and after chemotherapy were determined in order to 
speculate as to the usefulness of subsequent mAb therapy 
for these diseases.
The NK cell number was obtained through measurement 
by flow cytometry (3-color assay for CD45/CD16/CD56 
in CD3-negative fraction). Figure 4 in “Appendix” shows 
the representative FACS plot defined by CD16 and CD56. 
The lymphocyte gate was determined by side scatter-height 
(SSC-H) and CD45. The gated cells were displayed on a plot 
of CD16 versus CD56 expression. The double-positive frac-
tion of CD16/CD56 was defined as the NK cell. The NK cell 
number was calculated according to the following formula:
NK cell activity was obtained through measurement by 
51Cr release assay (an assay using the reaction of peripheral 
blood mononuclear cells (monocyte and lymphocyte) and 
51Cr-labeled K562 cells at an effector/target ratio of 20:1), 
and was calculated according to the following formula:
*(E - S)/(M - S) × 100, where E is the experimental release, 
S is the spontaneous release, and M is the maximum release.
Statistical analysis
Data were shown as box plots. For multiple comparison, 
Dwass, Steel, Critchlow–Fligner multiple comparison analysis 
was used as shown in Fig. 1. All statistical analyses were con-
ducted by SAS ver 9.4 (SAS Institute Inc., Cary, NC, USA).
Study oversight
The study was sponsored by Kyowa Hakko Kirin Co., 
Ltd. The academic investigators and the sponsor were 
jointly responsible for the study design. The protocol was 
NK cell number (/µL) = lymphocyte count (/µL)
× double-positive fraction of CD16/CD56 (%)× 0.01.
NK cell activity (%) = Specific lysis (%)∗
× double-positive fraction of CD16/CD56 (%)× 0.01
approved by the institutional review boards at each partici-
pating site, and the study was conducted complying with 
the ethical guidelines on clinical research and in accord-
ance with the Declaration of Helsinki 1995. The blood 
sample assays using flow cytometry and 51Cr release were 
outsourced to SRL Medisearch Inc. Data analysis was out-
sourced to Biostatistics center, Kurume university.
Results
Patient characteristics
The total number of patients enrolled was 26, and 25 
patients (14 patients with ATL and 11 patients with 
PTCL) were included in the data analysis. One patient 
was excluded from analysis due to a low initial lympho-
cyte count of 80/μL. Data from this patient were rejected 
because it was judged to be inappropriate to use this value 
as the basis for examination of variations, and calcula-
tion of the NK cell number and activity. Table 1 shows the 
Table 1  Patient demographics and clinical characteristics
AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large 
cell lymphoma, ALK anaplastic lymphoma kinase, ATL adult T-cell 
leukemia–lymphoma, CHOP cyclophosphamide, doxorubicin, vin-
cristine, and prednisone, CHOP/-L CHOP or CHOP-like regimen, 
EATL enteropathy-associated T-cell lymphoma, ECOG Eastern 
Cooperative Oncology Group, mLSG15 vincristine, cyclophospha-
mide, doxorubicin, prednisone and doxorubicin, ranimustine, pred-
nisone and vindesine, etoposide, carboplatin, prednisone, mLSG15/-L 
mLSG15 or mLSG15-like regimen, NOS not otherwise specified, PS 
performance status, PTCL peripheral T-cell lymphoma, SPTCL sub-
cutaneous panniculitis-like T-cell lymphoma
Characteristic ATL patients (n = 14) PTCL patients 
(n = 11)
n (%) n (%)
Age (years) Median 56 69
Range 47–72 36–78
Sex Male 9 (64) 9 (82)
Female 5 (36) 2 (18)
ECOG PS 0 2 (14) 5 (45)
1 9 (64) 4 (36)
2 2 (14) 2 (18)
3 0 (0) 0 (0)
4 1 (7) 0 (0)
Therapy CHOP/-L 5 (36) 11 (100)
mLSG15/-L 9 (64) 0 (0)
Subtype Acute 10 (71) AITL 5 (45)
Lymphoma 1 (7) PTCL-NOS 3 (27)
Chronic 3 (21) ALCL ALK- 1 (9)
EATL 1 (9)
SPTCL 1 (9)
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demographics and clinical characteristics of the 25 ana-
lyzed patients, and Table 2 shows the breakdown of patients 
on chemotherapy in relation to the disease subtype. The 
mLSG15/-L regimen was administered to 9 (64 %) patients 
with ATL. It should be noted that although the number of 
patients analyzed was limited, no marked difference was 
found in disease subtype according to the type of chemo-
therapy (mLSG15/-L vs. CHOP/-L). The CHOP/-L regi-
men was administered to all (100 %) patients with PTCL. 
Table 3 in “Appendix” shows the breakdown of ATL 
patients received with mLSG15/-L regimen and CHOP/-L 
regimen, and Table 4 in “Appendix” shows the breakdown 
of PTCL patients received with CHOP/-L regimen. Disease 
progressions were almost reasons for taken off these thera-
pies. None of ATL patients received both mLSG15/-L and 
CHOP/-L regimens.
Lymphocyte counts and NK cell number and activity 
before treatment initiation
Figure 1 shows the lymphocyte count, NK cell number, 
and NK cell activity determined in 14 patients with ATL, 
11 patients with PTCL, and 10 healthy adult volunteers. 
The lymphocyte count before initiation of treatment was 
significantly higher by 1 log in ATL compared to in PTCL 
patients (Fig. 1a), which was probably attributable to the fact 
that patients with acute-type ATL who had ATL cells in the 
peripheral blood [22] accounted for 71 % of the patients with 
ATL (Table 2). There was no significant difference in the 
number of CD16/CD56 double-positive NK cells which can 
contribute to ADCC of mogamulizumab, before treatment 
initiation between ATL and PTCL patients, or between these 
patients and healthy adult volunteers (Fig. 1b). Although the 
NK cell activity before treatment initiation was markedly 
lower in ATL than in PTCL patients (Fig. 1c), there was no 
significant difference in the NK cell activity between patients 
with PTCL and healthy adult volunteers (Fig. 1c).
Variations in the NK cell number and activity in ATL 
patients after treatment initiation
The NK cell number in patients with ATL was decreased as 
a result of the mLSG15/-L regimen, and this decrease was 
more prominent before VECP therapy (Day 15–17 of each 
cycle) than before VCAP therapy (Day 1 of each cycle) 
(Fig. 2a). The NK cell number in patients with ATL also 
decreased by the CHOP/-L regimen (Fig. 2c). However, the 
NK cell activity by the CHOP/-L regimen showed a ten-
dency to increase (Fig. 2d), although there was not marked 
difference by mLSG15/-L regimen (Fig. 2b).
Variations in NK cell number and activity in PTCL 
patients after treatment initiation
In PTCL patients, the NK cell number did not decrease 
by the CHOP/-L regimen (Fig. 3a), though the NK cell 
Table 2  Breakdown of patients 
on chemotherapy in relation to 
the disease subtype
AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, ALK anaplastic lym-
phoma kinase, ATL adult T-cell leukemia–lymphoma, CHOP cyclophosphamide, doxorubicin, vincristine, 
and prednisone; CHOP-L CHOP-like regimen, CHOP/-L CHOP or CHOP-like regimen, EATL enterop-
athy-associated T-cell lymphoma, mLSG15 vincristine, cyclophosphamide, doxorubicin, prednisone 
and doxorubicin, ranimustine, prednisone and vindesine, etoposide, carboplatin, prednisone, mLSG15/-
L mLSG15 or mLSG15-like regimen, NOS not otherwise specified, PTCL peripheral T-cell lymphoma, 
SPTCL subcutaneous panniculitis-like T-cell lymphoma
a THP-COP, vincristine, pirarubicin, cyclophosphamide, and prednisone





Acute 10 (71) 6 (43) 4 (29)
Lymphoma 1 (7) 1 (7) 0 (0)
Chronic 3 (21) 2 (14) 1 (7)





AITL 5 (45) 1 (9) 4 (36)
PTCL-NOS 3 (27) 1 (9) 2 (18)
ALCL ALK- 1 (9) 1 (9) 0 (0)
EATL 1 (9) 0 (0) 1 (9)
SPTCL 1 (9) 0 (0) 1 (9)
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number in patients with ATL decreased by this regimen 
(Fig. 2c). The NK cell activity in PTCL patients slightly 
decreased by the CHOP/-L regimen (Fig. 3b).
Discussion
In this study, the effects of first-line therapy for newly 
diagnosed ATL and PTCL patients on NK cells defined as 
CD16/CD56 double-positive ones can cause high ADCC 
for defucosylated antibodies such as mogamulizumab 
were evaluated using NK cell number and NK cell activ-
ity substitute functional cell vitality as indices. These data 
showed that the effects of chemotherapy on NK cells var-
ied according to the disease (ATL or PTCL) and the regi-
men used and/or the number of courses of chemotherapy 
(mLSG15/-L regimen or CHOP/-L regimen). Further-
more, it was also found that the NK cell activity before 
treatment initiation was markedly lower in ATL than in 
PTCL patients. This low activity of NK cell in ATL may 
be caused by suppression of NK cells by a subset of ATL 
cells functioning as Treg cells [23–25]. These results sug-
gest that it is more difficult for some therapeutic mAbs 
that require an effector function to exert their therapeutic 
effects in ATL compared to in PTCL, although the mecha-
nism of NK cell activity may be different from that of 
ADCC. However, it cannot be directly concluded that ther-
apeutic Abs are less likely to exert benefits in patients with 
ATL. In fact, the NK cell number in cases treated with the 
mLSG15/-L regimen tended to be restored before the ini-
tiation of each chemotherapeutic cycle (VCAP therapy) 
in comparison with before toward the end of each cycle 
(VECP therapy). This finding suggests that in cases where 
mAbs are combined with the mLSG15/-L regimen, some 
therapeutic mAbs may be more likely to exert their benefi-
cial effects when they are used before the initiation of each 
cycle. Additionally, the NK cell activity tended to increase 
after the CHOP/-L regimen than after the mLSG15/-L 
regimen in patients with previously untreated ATL. Thera-
peutic effect of the administered chemotherapy against 
more suppressive ATL cells compared to PTCL may result 
in increased vitality per cell of survived NK cells in ATL 
patients. However, the details of why CHOP/-L treat-
ment tended to produce better results compared to those 
of more potent intensive regimen, mLSG15/-L, are nec-
essary to carefully consider, while paying heed to direct 
effects on NK cells by each chemotherapy itself. There-
fore, it is not possible to determine which of the two regi-
mens, both of which consist of drugs with different soli-
tary effects, should be recommended as the most suitable 
Fig. 1  Lymphocyte count, natural killer (NK) cell number, and NK 
cell activity before treatment initiation as determined using flow 
cytometry (cell number) and a 51Cr release assay (activity). a The 
mean lymphocyte count in healthy volunteers, peripheral T-cell lym-
phoma (PTCL) patients, and adult T-cell leukemia–lymphoma (ATL) 
patients were 1580, 991, and 11,618/μL, respectively. b The NK cell 
number in healthy volunteers, PTCL patients, and ATL patients, the 
corresponding mean values were 262, 224, and 166/μL, respectively. 
c The NK cell activity values in healthy volunteers, PTCL patients, 
and ATL patients, the corresponding mean values were 8.8, 10.4, and 
1.4 %, respectively
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chemotherapy to be combined with therapeutic Abs. How-
ever, the CHOP/-L regimen, which was associated with a 
less prominent decrease in totally NK cell activity, seems 
to be more promising, assuming that patients respond sim-
ilarly to chemotherapy alone. Further investigations in a 
greater number of patients are needed, because this was a 
small-scale study.
Recently, it was carried out a phase II controlled clini-
cal study (clinical trial information: NCT01173887) to 
examine the effects of combination treatment using the 
mLSG15 regimen and mogamulizumab in patients with 
untreated ATL [26]. In that phase II study, mogamuli-
zumab was administered at intervals of 2 weeks (at the 
same time as VCAP and VECP administration) over four 
courses of the mLSG15 regimen (8 times in total), i.e., 
at the same times as the blood sampling was performed 
in the present study. The results showed that the com-
plete response rate and overall response rate in the 29 
patients administered mLSG15 + mogamulizumab ver-
sus the 24 patients administered the mLSG15 alone were 
52 versus 33 % and 86 versus 75 %, respectively, with 
mLSG15 combined with mogamulizumab showing better 
efficacy in both indices. These data indicated that com-
bining mogamulizumab with mLSG15 showed an addi-
tive effect with mLSG15, which tended to cause a greater 
decrease in NK cell number than the CHOP/-L regimen. 
Therefore, we speculate that mogamulizumab combina-
tion with the CHOP/-L regimen could also be beneficial 
for patients in whom the mLSG15 regimen is difficult 
to implement because of advanced age or for other rea-
sons. Further investigations are needed to examine this 
presumption.
On the other hand, in patients with PTCL, the decrease 
in NK cell number and activity after the standard chemo-
therapy, i.e., the CHOP/-L regimen, was relatively small, as 
compared to the CHOP/-L treated patients with ATL, who 
Fig. 2  Variations in natural killer (NK) cell number and NK cell 
activity in adult T-cell leukemia–lymphoma (ATL) patients. a NK cell 
number determined before (Pre) administration at VCAP (Day 1 of 
each cycle) and VECP (Day 15–17 of each cycle: ※) of mLSG15/-
L treatment initiation. b NK cell activity determined before (Pre) 
administration at VCAP (Day 1 of each cycle) and VECP (Day 15–17 
of each cycle: ※) of mLSG15/-L treatment initiation. c NK cell num-
ber determined before (Pre) administration at each cycle of CHOP/-
L treatment initiation. d NK cell activity determined before (Pre) 
administration at each cycle of CHOP/-L treatment initiation
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would be immune suppressive condition as seen in Fig. 1c 
which shows significant lower activity of NK cells in ATL 
patients compared to PTCL. This result suggests that the 
effect of combining therapeutic Abs with chemotherapy 
is considerably more promising in PTCL patients. Indeed, 
a phase II clinical study of alemtuzumab in combination 
with CHOP demonstrated favorable effects, with complete 
response and overall response rates in 24 patients of 71 and 
75 %, respectively [27]. The efficacy of mogamulizumab in 
combination with CHOP in patients with untreated primary 
PTCL is also expected.
In conclusion, the results of the present study provide 
an important basis for future investigations of the com-
bined effects of chemotherapy and therapeutic Abs [18–20] 
whose activity is affected by CD16/CD56 double-positive 
NK cells. Further analysis of CD16-positive other effector 
cells which antibodies bind also remains to be explored to 
fully understand the combination effects.
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Appendix
See Tables 3, 4 and Fig. 4.
Fig. 3  Variations in natural killer (NK) cell number and NK cell 
activity in peripheral T-cell lymphoma (PTCL) patients. a NK cell 
number determined before (Pre) administration at each cycle of 
CHOP/-L treatment initiation. b NK cell activity determined before 
(Pre) administration at each cycle of CHOP/-L treatment initiation
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Table 3  Breakdown of ATL 
patients received with (a) VCAP 
(Day 1 of each cycle) and VECP 
(Day 15–17 of each cycle: ※) 
of mLSG15/-L regimen, (b) 
CHOP/-L regimen
Cycle number
1 1※ 2 2※ 3 3※ 4 4※
(a)
 Number of received patients 9 8 8 8 7 6 5 2
 Number of analyzed patients 9 8 8 8 7 6 5 2
 Number of missing data – 1 0 0 0 0 0 0
 Number of taken off therapy – 0 1 1 2 3 4 7
Cycle number
1 2 3 4 5 6 7 8
(b)
 Number of received patients 5 5 3 2 2 0 1 1
 Number of analyzed patients 5 5 3 2 2 0 1 1
 Number of missing data – 0 0 0 0 2 0 0
 Number of taken off therapy – 0 2 3 3 3 4 4
Table 4  Breakdown of PTCL 
patients received with CHOP/-L 
regimen
Cycle number
1 2 3 4 5 6 7 8
Number of received patients 11 11 8 9 7 7 6 6
Number of analyzed patients 10 10 7 9 7 7 6 6
Number of missing data – 0 2 0 1 1 1 0
Number of taken off therapy – 0 1 1 2 2 3 4
Fig. 4  Representative FACS 
plot defined by CD16 and 
CD56. a Isotype control and b 
representative sample for ATL 
patients
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